Patents Assigned to Genentech, Inc.
  • Compounds, compositions and methods for the treatment of diseases characterized by A-33 related antigens
    Patent number: 7115713
    Abstract: The present invention relates to compositions and methods of treating and diagnosing disorders characterized the by the presence of antigens associated with inflammatory diseases and/or cancer, and nucleotide sequences, including expressed sequence tags (ESTs), oligonucleotide probes, polypeptides, vectors and host cells expressing such antigens PRO301, PRO362 or PRO245.
    Type: Grant
    Filed: February 24, 2004
    Date of Patent: October 3, 2006
    Assignee: Genentech, Inc.
    Inventors: Avi Ashkenazi, Sherman Fong, Audrey Goddard, Austin L. Gurney, Mary A. Napier, Daniel Tumas, William I. Wood
  • Transgenic mice expressing human cd20 and/or cd16
    Publication number: 20060218655
    Abstract: The present invention generally relates to non-human transgenic animals expressing human cellular markers, including CD20 and/or preferably CD16.
    Type: Application
    Filed: December 11, 2003
    Publication date: September 28, 2006
    Applicant: Genentech, Inc.
    Inventors: Andrew Chan, Qian Gong, Flavius Martin
  • Compositions with hematopoietic and immune activity
    Publication number: 20060217301
    Abstract: The present invention provides methods of using Bv8 and EG-VEGF polypeptides and nucleic acids to promote hemtopoiesis. Also provided herein are methods of screening for modulators of Bv8 and EG-VEGF activity. Furthermore, methods of treatment using Bv8 and EG-VEGF polypeptides or Bv8 and EG-VEGF antagonists are provided.
    Type: Application
    Filed: March 12, 2004
    Publication date: September 28, 2006
    Applicant: GENENTECH, INC.
    Inventors: Napoleone Ferrara, Jennifer Lecouter
  • DNA 19355 polypeptide, a tumor necrosis factor homolog
    Publication number: 20060216270
    Abstract: A tumor necrosis factor homolog, identified as DNA19355, is provided. DNA19355 polypeptide has apoptotic activity in mammalian cancer cells and may be involved in proinflammatory responses. Nucleic acid molecules encoding DNA19355, chimeric molecules and antibodies to DNA19355 are also provided.
    Type: Application
    Filed: February 14, 2006
    Publication date: September 28, 2006
    Applicant: Genentech, Inc.
    Inventors: Avi Ashkenazi, Kevin Baker, Paul Godowski, Austin Gurney, Melanie Mark, Scot Marsters, Robert Pitti
  • PRO1312 polypeptides
    Patent number: 7112656
    Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Grant
    Filed: November 15, 2001
    Date of Patent: September 26, 2006
    Assignee: Genentech, Inc.
    Inventors: Luc Desnoyers, Audrey Goddard, Paul J. Godowski, Austin L. Gurney, William I. Wood
  • PRO697 polypeptides
    Patent number: 7112657
    Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Grant
    Filed: October 19, 2001
    Date of Patent: September 26, 2006
    Assignee: Genentech, Inc.
    Inventors: Audrey Goddard, Paul J. Godowski, Austin L. Gurney, James Pan, William I. Wood
  • Novel composition and methods for the treatment of immune disorders
    Publication number: 20060210556
    Abstract: The present invention relates to compositions of matter and methods for the treatment and diagnosis of immune related diseases, including those mediated by cytokines released primarily either Th1 or Th2 cells in response to antigenic stimulation. The present invention further relates to methods for biasing the differentiation of T-cells in either the Th1 subtype or the Th2 subtype based on the relative expression levels of the gene PRO92726, and its agonists or antagonists. The present invention further relates to a method of diagnosing Th1- and Th2-mediated diseases.
    Type: Application
    Filed: April 8, 2004
    Publication date: September 21, 2006
    Applicant: Genentech, Inc.
    Inventors: Daryl Baldwin, Hilary Clark, Henry Chiu, Grazyna Fedorowicz, Sherman Fong, J. Grimaldi, Wenjun Quyang, P. Williams
  • Nucleic acids encoding PRO830
    Patent number: 7109318
    Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Grant
    Filed: November 16, 2001
    Date of Patent: September 19, 2006
    Assignee: Genentech, Inc.
    Inventors: David Botstein, Audrey Goddard, Paul J. Godowski, Austin L. Gurney, Margaret Ann Roy, Colin K. Watanabe, William I. Wood
  • Secreted and transmembrane polypeptides and nucleic acids encoding the same
    Patent number: 7109305
    Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Grant
    Filed: April 17, 2002
    Date of Patent: September 19, 2006
    Assignee: Genentech, Inc.
    Inventors: Kevin P. Baker, Maureen Beresini, Laura DeForge, Luc Desnoyers, Ellen Filvaroff, Wei-Qiang Gao, Mary E. Gerritsen, Audrey Goddard, Paul J. Godowski, Austin L. Gurney, Steven Sherwood, Victoria Smith, Timothy A. Stewart, Daniel Tumas, Colin K. Watanabe, William I. Wood, Zemin Zhang
  • Halo-alkoxycarbonyl prodrugs
    Patent number: 7109326
    Abstract: Halo-alkoxycarbonyl derivatives are provided as prodrug moieties for pharmaceutical agents containing a basic or polar nitrogen containing functionality. The prodrugs are provided as pharmaceutical compositions as well as in methods of treatment.
    Type: Grant
    Filed: May 25, 2004
    Date of Patent: September 19, 2006
    Assignee: Genentech, Inc.
    Inventors: Brent Blackburn, Alan G. Olivero, Kirk Robarge
  • Secreted and transmembrane polypeptides and nucleic acids encoding the same
    Patent number: 7109292
    Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Grant
    Filed: May 1, 2002
    Date of Patent: September 19, 2006
    Assignee: Genentech, Inc.
    Inventors: Audrey Goddard, Paul J. Godowski, Austin L. Gurney, William I. Wood
  • Bv8 nucleic acids and polypeptides with mitogenic activity
    Publication number: 20060204510
    Abstract: The present invention provides methods of using Bv8 polypeptides to induce endothelial cell proliferation and to enhance endothelial cell survival. Also provided herein are methods of screening for modulators of Bv8 activity. Furthermore, methods of treatment using Bv8 polypeptides are provided.
    Type: Application
    Filed: March 17, 2006
    Publication date: September 14, 2006
    Applicant: Genentech, Inc.
    Inventors: Napoleone Ferrara, Jennifer Le Couter
  • GDNF receptor?
    Patent number: 7105484
    Abstract: GDNFR?, GDNFR? extracellular domain (ECD), GDNFR? variants, chimeric GDNFR? (e.g., GDNFR? immunoadhesin), and antibodies which bind thereto (including agonist and neutralizing antibodies) are disclosed. Various uses for these molecules are described, including methods to modulate cell activity and survival by response to GDNFR?-ligands, for example GDNF, by providing GDNFR? to the cell. Also provided are methods for using GDNFR?, GDNF, or agonists thereof, separately or in complex, to treat kidney diseases.
    Type: Grant
    Filed: November 2, 2001
    Date of Patent: September 12, 2006
    Assignee: Genentech, Inc.
    Inventors: Robert D. Klein, Mark W. Moore, Arnon Rosenthal, Anne M. Ryan
  • Secreted and transmembrane polypeptides and nucleic acids encoding the same
    Patent number: 7105335
    Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Grant
    Filed: April 17, 2002
    Date of Patent: September 12, 2006
    Assignee: Genentech, Inc.
    Inventors: Audrey Goddard, Paul J. Godowski, Austin L. Gurney, William I. Wood
  • Anti-pro792 antibodies
    Patent number: 7105640
    Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Grant
    Filed: October 19, 2001
    Date of Patent: September 12, 2006
    Assignee: Genentech, Inc.
    Inventors: Luc Desnoyers, Audrey Goddard, Paul J. Godowski, Austin L. Gurney, William I. Wood
  • Anti-PRO 4405 antibodies
    Patent number: 7105639
    Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Grant
    Filed: December 26, 2001
    Date of Patent: September 12, 2006
    Assignee: Genentech, Inc.
    Inventors: Luc Desnoyers, Audrey Goddard, Paul J. Godowski, Austin L. Gurney, William I. Wood
  • Methods for treating clinical manifestations of GH/GF axis dysregulation by administration of an IGF-I variant
    Patent number: 7105167
    Abstract: IGF-I variants having an alanine, glycine, or serine amino acid residue at position 16, 25, 49 or at positions 3 and 49 of native-sequence IGF-I are provided that are useful to treat a disorder characterized by dysregulation of the GH/IGF axis in a mammal, such as a renal disorder.
    Type: Grant
    Filed: December 19, 2001
    Date of Patent: September 12, 2006
    Assignee: Genentech, Inc.
    Inventors: Yves Dubaquie, Paul J. Fielder, Henry B. Lowman, Deborah L. Mortensen
  • Nucleic acids encoding PRO943
    Patent number: 7101687
    Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Grant
    Filed: November 16, 2001
    Date of Patent: September 5, 2006
    Assignee: Genentech, Inc.
    Inventors: Luc Desnoyers, Audrey Goddard, Paul J. Godowski, Austin L. Gurney, William I. Wood
  • Secreted and transmembrane polypeptides and nucleic acids encoding the same
    Patent number: 7101984
    Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Grant
    Filed: December 27, 2001
    Date of Patent: September 5, 2006
    Assignee: Genentech, Inc.
    Inventors: David Botstein, Luc Desnoyers, Napoleone Ferrara, Sherman Fong, Wei-Qiang Gao, Audrey Goddard, Austin L. Gurney, James Pan, Margaret Ann Roy, Timothy A. Stewart, Daniel Tumas, Colin K. Watanabe, William I. Wood
  • IgE receptor antagonists
    Patent number: 7101851
    Abstract: The invention provides novel compounds which bind to the high affinity receptor for immunoglobulin E (IgE) designated Fc?RI and methods for identifying and preparing such compounds. In particular aspects, the invention provides to the treatment of disorders mediated by IgE utilizing the novel compounds of the invention. The invention also provides composition, such as pharmaceutical compositions, comprising the novel compounds, as well as for their use in research, diagnostic, therapeutic, and prophylactic methods.
    Type: Grant
    Filed: September 26, 2001
    Date of Patent: September 5, 2006
    Assignee: Genentech, Inc.
    Inventors: Henry B. Lowman, Gerald R. Nakamura, Mark E. Reynolds, Melissa A. Starovasnik